Welcome to our dedicated page for Cutera news (Ticker: CUTR), a resource for investors and traders seeking the latest updates and insights on Cutera stock.
Cutera Inc (CUTR) is a global leader in medical aesthetics, pioneering advanced laser systems for skin treatments and body contouring. This page serves as the definitive source for official company announcements, financial disclosures, and technology developments.
Access real-time updates on earnings reports, FDA clearances, product launches, and strategic partnerships. Investors and practitioners alike rely on this centralized hub for tracking innovations in energy-based aesthetic devices and corporate milestones.
Our curated news feed includes clinical study results, regulatory updates, and market expansion announcements. Stay informed about CUTR's advancements in ND:YAG technology and international service network developments through verified primary sources.
Bookmark this page for streamlined access to CUTR's evolving position in the $6B medical aesthetics sector. Check regularly for critical updates affecting treatment protocols, device safety profiles, and corporate financial health.
Cutera, Inc. (NASDAQ: CUTR) has announced that it is now in compliance with Nasdaq Listing Rule 5250(c)(1), following the filing of its Form 10-K for the period ended December 31, 2022. Previously, the company received a notification of non-compliance due to a delayed filing. The recent Form 10-K does not contain any restatements of prior financial statements and discloses no additional material weaknesses in internal controls beyond those previously reported on March 16, 2023. This compliance reaffirms Cutera’s commitment to meeting Nasdaq's requirements. The company is recognized for its innovative aesthetic and dermatology solutions, offering safe and effective treatments for practitioners worldwide since 1998.
Cutera, Inc. has faced significant governance issues as highlighted by Executive Chairman J. Daniel Plants and CEO David Mowry, who together own 7% of the company. They have called for a Special Meeting of Stockholders to address the removal of several board members, citing dysfunction and failure in CEO succession planning. Mowry expressed concerns over the board's inability to agree on a successor and its lack of transparency, while Plants criticized the board's political behavior. This turmoil has hindered long-term decision-making and strategy implementation, resulting in a factionalized board. They aim to enable shareholders to vote on new board representation, emphasizing the urgency for change to restore confidence and strategic direction at CUTR.
Cutera, Inc. (NASDAQ: CUTR), a leader in aesthetic solutions, has responded to a demand from Executive Chairman J. Daniel Plants for a special meeting of stockholders. This meeting seeks to remove the majority of the Board of Directors without cause. In response, Cutera's Board has formed a Special Committee of independent directors to review the demand. The Special Committee is committed to acting in the best interests of the company and its stockholders, and it will provide a formal recommendation soon. As of now, stockholders are not required to take any action. Wilson Sonsini and Sidley Austin LLP are serving as legal counsel to the Company and the Special Committee, respectively.
Cutera, a leading provider of aesthetic solutions, received a notice from Nasdaq on March 21, 2023, indicating non-compliance with listing rules due to late filing of its Form 10-K for the year ending December 31, 2022. The original due date was March 16, 2023. Cutera has 60 days from receipt of the notice to submit a compliance plan, with a potential extension until September 12, 2023, if accepted. The company is diligently working to file the Form 10-K as soon as possible. The notice does not impact current trading or listing status.
CUTERA, INC. (Nasdaq: CUTR) has unveiled an updated truBody brand, enhancing its marketing and patient experience through a new website, campaign, and social media presence. The brand refresh includes the renaming of key treatments: truSculpt® for fat reduction and truFlex™ for muscle toning, alongside the introduction of the Trim & Tone protocol, featuring one truSculpt and four truFlex sessions. This initiative aims to boost market visibility and improve patient outcomes, as highlighted by senior executives and practitioners emphasizing truBody's positive impact.
Cutera, Inc. (CUTR) reported Q4 and full-year 2022 financial results, showing consolidated revenue of $67.4 million in Q4, a 3% increase year-over-year. Full-year revenue reached $252.4 million, a 16% increase in constant currency. Notably, AviClear generated $4.5 million in revenue. However, the company reported a GAAP net loss of $82.3 million for 2022, significantly higher than a profit of $2.1 million in 2021. For 2023, Cutera forecasted revenue between $277 million and $292 million, indicating 10% to 16% growth.
Cutera, Inc. (CUTR), a provider of aesthetic and dermatology solutions, will announce its fourth quarter and full year 2022 financial results after market close on February 28, 2023. The management will discuss these results in a conference call at 1:30 p.m. PT the same day. Investors can join the call via phone or by accessing the webcast through Cutera’s website. Founded in 1998 and based in Brisbane, California, Cutera develops innovative products for medical practitioners to offer safe treatments. More information is available on their website.
Cutera, Inc. (CUTR) released preliminary financial results for the year ended December 31, 2022, expecting revenues between $252 million to $253 million, reflecting a growth of 15% to 16% year-over-year. This is lower than previous guidance of $255 million to $260 million. The final results will be disclosed on February 28, 2023, during a conference call. Additionally, Cutera management will be engaging with investors from January 10-12, 2023, at the Nasdaq offices in San Francisco.
Cutera, Inc. announced the pricing of $100 million in convertible senior notes due 2029 at a 4.00% interest rate. The notes will close on December 12, 2022, and include an option for initial purchasers to buy an additional $20 million. Proceeds are expected to be approximately $96.4 million, intended for general corporate purposes, including acquisitions and working capital. The initial conversion price is set at $58.35 per share. The company may redeem the notes after December 5, 2025, under specific conditions.
Cutera, Inc. (NASDAQ: CUTR) announced plans to offer $100 million in convertible senior notes due 2029 to qualified institutional buyers. The offering may include an additional $20 million at the initial purchasers' option. Proceeds will cover the costs of capped call transactions and fund general corporate purposes, including working capital, acquisitions, and potential stock repurchases. The notes are unsecured and will be convertible into cash or common stock. Notably, this offering aims to mitigate potential dilution of shares upon conversion.
